Literature DB >> 23201048

Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole.

Thomas Taupitz1, Jennifer B Dressman, Charles M Buchanan, Sandra Klein.   

Abstract

The aim of the present series of experiments was to improve the solubility and dissolution/precipitation behaviour of a poorly soluble, weakly basic drug, using itraconazole as a case example. Binary inclusion complexes of itraconazole with two commonly used cyclodextrin derivatives and a recently introduced cyclodextrin derivative were prepared. Their solubility and dissolution behaviour was compared with that of the pure drug and the marketed formulation Sporanox®. Ternary complexes were prepared by addition of Soluplus®, a new highly water soluble polymer, during the formation of the itraconazole/cyclodextrin complex. A solid dispersion made of itraconazole and Soluplus® was also studied as a control. Solid state analysis was performed for all formulations and for pure itraconazole using powder X-ray diffraction (pX-RD) and differential scanning calorimetry (DSC). Solubility tests indicated that with all formulation approaches, the aqueous solubility of itraconazole formed with hydroxypropyl-β-cyclodextrin (HP-β-CD) or hydroxybutenyl-β-cyclodextrin (HBen-β-CD) and Soluplus® proved to be the most favourable formulation approaches. Whereas the marketed formulation and the pure drug showed very poor dissolution, both of these ternary inclusion complexes resulted in fast and extensive release of itraconazole in all test media. Using the results of the dissolution experiments, a newly developed physiologically based pharmacokinetic (PBPK) in silico model was applied to compare the in vivo behaviour of Sporanox® with the predicted performance of the most promising ternary complexes from the in vitro studies. The PBPK modelling predicted that the bioavailability of itraconazole is likely to be increased after oral administration of ternary complex formulations, especially when itraconazole is formulated as a ternary complex comprising HP-β-CD or HBen-β-CD and Soluplus®.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23201048     DOI: 10.1016/j.ejpb.2012.11.003

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  11 in total

Review 1.  Multifunctional Role of Polyvinylpyrrolidone in Pharmaceutical Formulations.

Authors:  Yu Luo; Yanlong Hong; Lan Shen; Fei Wu; Xiao Lin
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

2.  Formulation of Apigenin-Cyclodextrin-Chitosan Ternary Complex: Physicochemical Characterization, In Vitro and In Vivo Studies.

Authors:  Mohammed Jafar; Mohammed Saifuddin Khalid; Hajer Alghamdi; Mohd Amir; Sarah Aon Al Makki; Ohud Saud Alotaibi; Afnan Ali Al Rmais; Syed Sarim Imam; Sultan Alshehri; Sadaf Jamal Gilani
Journal:  AAPS PharmSciTech       Date:  2022-02-10       Impact factor: 3.246

3.  Development of intramammary delivery systems containing lasalocid for the treatment of bovine mastitis: impact of solubility improvement on safety, efficacy, and milk distribution in dairy cattle.

Authors:  Wen Wang; Yunmei Song; Kiro Petrovski; Patricia Eats; Darren J Trott; Hui San Wong; Stephen W Page; Jeanette Perry; Sanjay Garg
Journal:  Drug Des Devel Ther       Date:  2015-01-22       Impact factor: 4.162

4.  Supersaturable solid self-microemulsifying drug delivery system: precipitation inhibition and bioavailability enhancement.

Authors:  Guilan Quan; Boyi Niu; Vikramjeet Singh; Yixian Zhou; Chuan-Yu Wu; Xin Pan; Chuanbin Wu
Journal:  Int J Nanomedicine       Date:  2017-12-13

5.  Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model.

Authors:  Yuan Chen; Tamara D Cabalu; Ernesto Callegari; Heidi Einolf; Lichuan Liu; Neil Parrott; Sheila Annie Peters; Edgar Schuck; Pradeep Sharma; Helen Tracey; Vijay V Upreti; Ming Zheng; Andy Z X Zhu; Stephen D Hall
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-08-07

6.  Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.

Authors:  Denise Türk; Nina Hanke; Sarah Wolf; Sebastian Frechen; Thomas Eissing; Thomas Wendl; Matthias Schwab; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

7.  Formulation of a film-coated dutasteride tablet bioequivalent to a soft gelatin capsule (Avodart®): Effect of γ-cyclodextrin and solubilizers.

Authors:  Mi-Hong Min; Jin-Hyong Park; Mi-Ran Choi; Jong-Hyun Hur; Byung-Nak Ahn; Dae-Duk Kim
Journal:  Asian J Pharm Sci       Date:  2018-10-05       Impact factor: 6.598

8.  Development of Liposome containing sodium deoxycholate to enhance oral bioavailability of itraconazole.

Authors:  Zhenbao Li; Meiyu Zhang; Chang Liu; Shiwei Zhou; Wenjuan Zhang; Tianyang Wang; Mei Zhou; Xiaohong Liu; Yongjun Wang; Yinghua Sun; Jin Sun
Journal:  Asian J Pharm Sci       Date:  2016-08-04       Impact factor: 6.598

9.  Prediction of Free Drug Absorption in Cyclodextrin Formulation by a Modified Physiologically Based Pharmacokinetic Model and Phase Solubility 3-D Surface Graph.

Authors:  Wei Wang; Defang Ouyang
Journal:  Pharm Res       Date:  2021-06-18       Impact factor: 4.200

10.  Formulation of Genistein-HP β Cyclodextrin-Poloxamer 188 Ternary Inclusion Complex: Solubility to Cytotoxicity Assessment.

Authors:  Ameeduzzafar Zafar; Nabil K Alruwaili; Syed Sarim Imam; Omar Awad Alsaidan; Faisal K Alkholifi; Khalid Saad Alharbi; Ehab M Mostafa; Abdullah S Alanazi; Sadaf Jamal Gilani; Arafa Musa; Sultan Alshehri; Alenazy Rawaf; Ali Alquraini
Journal:  Pharmaceutics       Date:  2021-11-24       Impact factor: 6.525

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.